Comparative Pharmacology
Head-to-head clinical analysis: AN DTPA versus SELENOMETHIONINE SE 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AN DTPA versus SELENOMETHIONINE SE 75.
AN-DTPA vs SELENOMETHIONINE SE 75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AN-DTPA (pentetate calcium trisodium) is a chelating agent that binds to and removes heavy metals, such as plutonium, americium, curium, and other transuranic elements, from the body. It forms stable complexes with these metals, which are then excreted via the kidneys.
Radiopharmaceutical agent: selenium-75 decays by electron capture to arsenic-75 with emission of gamma photons. Used as a tracer for pancreatic imaging due to incorporation into pancreatic enzymes. Localizes in pancreas via protein synthesis.
1 gram by intravenous injection or infusion daily for 5 consecutive days, starting immediately after the end of radiotherapy.
0.185-0.37 MBq (5-10 μCi) intravenously as a single dose for pancreatic imaging.
None Documented
None Documented
Terminal elimination half-life: approximately 1.5-2 hours in patients with normal renal function. Extended significantly in renal impairment (up to 24 hours in anuria).
Terminal half-life is approximately 50-60 days, reflecting slow turnover of selenomethionine incorporated into body proteins (e.g., skeletal muscle, erythrocytes).
Renal: >95% as unchanged drug via glomerular filtration. Biliary/fecal: <5%.
Primarily renal, with 20-30% excreted unchanged in urine; minor fecal elimination (<5%). The remainder is incorporated into endogenous proteins and long-term tissue stores.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical